Chronic Urticaria - Pipeline Insight, 2024

Chronic Urticaria - Pipeline Insight, 2024

DelveInsight’s, “Chronic Urticaria - Pipeline Insight, 2024,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Chronic Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Urticaria Understanding

Chronic Urticaria: Overview

Chronic urticaria is defined as daily itchy wealing of the skin for more than six weeks. Chronic urticaria may be spontaneous or inducible, which may co-exist. Chronic urticaria can affect children and adults. Chronic inducible urticaria is more common than chronic spontaneous urticaria. Adults with chronic urticaria have a significantly higher prevalence of atopic dermatitis, asthma, and allergic rhinitis than a control population. In children, the prevalence of atopy is similar in those with chronic urticaria as the general population. Chronic spontaneous urticaria affects 0.5–2% of the population; in some series, two-thirds are women. There are genetic and autoimmune associations. Weals are due to release of chemical mediators from tissue mast cells and circulating basophils. These chemical mediators include histamine, platelet-activating factor, and cytokines. The mediators activate sensory nerves and cause dilation of blood vessels and leakage of fluid into surrounding tissues. Bradykinin release causes angioedema. Several hypotheses have been proposed to explain urticaria. The immune, arachidonic acid and coagulation systems are involved, and genetic mutations are under investigation. Chronic spontaneous urticaria is mainly idiopathic (cause unknown). An autoimmune cause is likely. About half of investigated patients carry functional IgG autoantibodies to immunoglobulin IgE or high-affinity receptor FcεRIα.

""Chronic Urticaria - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Urticaria pipeline landscape is provided which includes the disease overview and Chronic Urticaria treatment guidelines. The assessment part of the report embraces, in depth Chronic Urticaria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Urticaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Chronic Urticaria.
• In the coming years, the Chronic Urticaria market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Chronic Urticaria R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Chronic Urticaria treatment market. Several potential therapies for Chronic Urticaria are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Chronic Urticaria market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Chronic Urticaria) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chronic Urticaria Emerging Drugs Chapters

This segment of the Chronic Urticaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Urticaria Emerging Drugs

• Remibrutinib: Novartis

Remibrutinib is a highly selective, potent oral BTK inhibitor discovered within Novartis⁶´⁷ and being developed in a number of clinical and early settings. With an unmet need for new CSU therapies, highlighting the importance of targeting new modes of action, BTK inhibition may be an attractive therapeutic option for CSU, due to its pivotal role in FcεR1-mediated (high affinity receptor of IgE) signalling of mast cells and basophils and their relevance to chronic spontaneous urticaria (CSU) pathogenesis. The drug is currently in Phase III stage of clinical trial evaluation to treat chronic spontaneous urticaria.

• SYN008: Synermore Biologics

SYN008 is a biosimilar of Omalizumab (Xolair; a humanized anti-immunoglobulin E monoclonal antibody). It binds to the free IgE molecules in serum, thereby blocking the interaction between IgE and effector cells, which trigger the allergic response irrespective of allergen type. Stringent comparability studies between SYN008 and Omalizumab have been conducted and the investigational new drug (IND) application of SYN008 has been filed to the China Food and Drug Administration (CFDA) in Oct 2014. The phase I clinical trial has been completed in Australia in Sep 2016. The drug is currently in Phase III stage of clinical trial evaluation to treat chronic spontaneous urticaria.

Further product details are provided in the report……..

Chronic Urticaria: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Urticaria drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Chronic Urticaria

There are approx. 22+ key companies which are developing the therapies for Chronic Urticaria. The companies which have their Chronic Urticaria drug candidates in the most advanced stage, i.e. phase III include, Novartis.

• Phases

DelveInsight’s report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Chronic Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Urticaria: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Urticaria therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Urticaria drugs.

Chronic Urticaria Report Insights

• Chronic Urticaria Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Urticaria Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Urticaria drugs?
• How many Chronic Urticaria drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Urticaria?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Urticaria therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Urticaria and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis
• Synermore Biologics
• Teva Pharmaceuticals
• Regeneron Pharmaceuticals
• Celltrion
• United BioPharma
• Glenmark Pharmaceuticals
• UCB Biopharma
• GI Innovation
• Celldex Therapeutics
• Eli Lilly and Company
• Amgen
• ValenzaBio
• Third Harmonic Bio
• Inmagene
• Lanier Biotherapeutics

Key Products

• Remibrutinib
• SYN008
• Ligelizumab
• TEV-45779
• Dupilumab
• CT-P39
• UB-221
• GBR 310
• UCB8600
• GI-301
• CDX-0159
• LY3454738
• Tezepelumab
• VB517
• THB001
• IMG 036
• LNR 125.38